No Data
China International Capital Corp: Maintains CUTIA-B (02487) outperform industry rating and lowers Target Price to 9.31 HKD.
The bank believes that the subsequent dense pipeline launch is expected to contribute to performance growth, and is Bullish on the company's medium to long-term growth potential in becoming a skin management platform.
CUTIA-B rose by 6% after the performance, with an annual income of approximately 0.28 billion yuan, an increase of about 103% year-on-year.
CUTIA-B (02487) rose 6% after earnings announcement, currently reported at 6.36 HKD, with a transaction amount of 6.4506 million HKD. On March 24th, CUTIA-B announced its 2024 performance, with revenues of approximately 0.28 billion yuan, an increase of about 103% year-on-year. Gross profit was approximately 0.1435 billion yuan, an increase of about 102.0% year-on-year. The net loss was approximately 0.434 billion yuan, a narrowing of 77.91% year-on-year. Loss per share was 1.41 yuan. The announcement stated that the revenue growth was mainly due to increased sales of hair disease and care products, as well as daily skincare products. 2024 will be the company's second full year of commercialization, leveraging the company's strong products.
CUTIA-B (02487.HK): In the fiscal year 2024, revenue increased by 103% year-on-year to 0.28 billion yuan.
On March 24th, Gelonghui reported that CUTIA-B (02487.HK) announced that for the year ending December 31, 2024, revenue is expected to increase by approximately 103% year-on-year to about 0.28 billion yuan, mainly due to increased sales of hair disease and care products as well as daily skincare products. The group's existing sales channels have shown initial economies of scale, and the group has achieved good results in cost control. For the year ending December 31, 2024, the proportion of sales and distribution expenses to revenue has significantly decreased compared to the same period last year; R&D costs have decreased by approximately 17 million yuan or 8% compared to the same period last year; administrative expenses...
CUTIA-B (02487) announced its 2024 performance, with a net loss of approximately 0.434 billion yuan, narrowing by 77.91% year-on-year.
CUTIA-B (02487) announced its 2024 performance, with revenues of approximately 0.28 billion yuan, an increase of about 103% year-on-year. Gross...
Express News | Cutia Therapeutics - FY Revenue RMB280 Mln
CUTIA-B: ANNUAL RESULTS ANNOUNCEMENTFOR THE YEAR ENDED 31 DECEMBER 2024
良辰（岗） : Congrats ur 8206
I like to move it OP 良辰（岗） : Thank you.